Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Eur Rev Med Pharmacol Sci ; 28(7): 2750-2759, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38639514

ABSTRACT

OBJECTIVE: Hyperglycemic mothers and their offspring are at increased risk of various maternal and neonatal complications such as macrosomia, future type 2 diabetes, and metabolic abnormalities. Early diagnosis and individualized dietary management, exercise, and emotional well-being are expected to reduce these risks. The study aims to identify the effect of the Nutrition and Behavior Modification Program (NBMP) on maternal and neonatal outcomes of hyperglycemic mothers. PATIENTS AND METHODS: A pre-experimental study was performed among 89 hyperglycemic mothers. Glycemic control at 28 and 36 weeks, weight gain during pregnancy, pre-eclampsia, pregnancy-induced hypertension (PIH), mode of delivery, duration of exercise, emotional well-being, neonates' birth weight, incidence of hypoglycemia, and NICU admission were compared among the study and control groups. The intervention group received an individualized NBMP from their diagnosis of hyperglycemia until delivery. RESULTS: The results showed a significant difference in blood glucose between the study periods and groups at p<0.05 as per repeated ANOVA. Also, diet scores had a significant influence on BMI and glycemic control at p<0.05. Logistic regression models, adjusted for potential confounders including baseline blood glucose, age, economic status, previous GDM, family history of DM as well as baseline BMI, diet score, physical activity, and maternal well-being score, indicated that the NBMP reduced the blood glucose and BMI significantly at p<0.05 in the study group. NBMP also reduced the risk of SGA/LGA and preterm/post-mature birth, as well as increased the exercise duration and emotional well-being of mothers. CONCLUSIONS: The study's conclusions draw attention to the possible roles that maternal wellness, physical activity, and diet may have in reducing risks for both hyperglycemic mothers and their newborns. The NBMP resulted in higher adherence to lifestyle changes. Further research on a larger sample of hyperglycemic mothers is recommended to expand the generalizability of the findings.


Subject(s)
Diabetes Mellitus, Type 2 , Diabetes, Gestational , Pregnancy , Female , Infant, Newborn , Humans , Blood Glucose/metabolism , Fetal Macrosomia/epidemiology , Behavior Therapy
2.
Eur Rev Med Pharmacol Sci ; 27(16): 7840-7850, 2023 08.
Article in English | MEDLINE | ID: mdl-37667961

ABSTRACT

OBJECTIVE: Many countries, including the USA, are currently confronting a triple epidemic in children as COVID-19 cases increase and new strains emerge which urge COVID-19 vaccination for children. The Advisory Committee on Immunization Practices (ACIP) for the CDC unanimously approved the inclusion of the COVID-19 vaccine (C19V) in the recommended immunizations. As healthcare professionals (HCPs) and parents are significant players in changing the trend of the triple epidemic by giving the C19V, the present study was done to determine awareness and perception of HCPs and parents on the tripledemic and the need for inclusion of C19V in vaccination schedules for children. PATIENTS AND METHODS: A cross-sectional study was conducted among 400 HCPs and 200 parents to assess their knowledge and perception of tripledemic and the need for the inclusion of C19V. RESULTS: Noticeably, half of the participants had either recent personal (36.2%) or family (21.8%) exposure to some of the tripledemic like RSV, Flu, or COVID-19. On perceived awareness, 42% were concerned about tripledemic, and 35% thought that regular C19V may prevent or reduce tripledemic. Ironically, 11% were not willing to give C19V to their children. The logistic regression model for positive perception of tripledemic and regular C19V identified significant relationships with education (OR 2.19, CI 1.48-3.81), gender (OR 0.9, CI 01.02-2.63), recent personal or family exposure to any of the tripledemic (OR 0.239, CI 0.87-1.63) and presence of children in the family (OR 0.71, CI 1.4-1.96). The reason for favorable perception was preventing self and family from tripledemic. CONCLUSIONS: The findings may give insight to the policymakers for a strategic plan to include C19V in the routine schedule to combat the pandemic and tripledemic by improving herd immunity.


Subject(s)
COVID-19 Vaccines , COVID-19 , Humans , Child , COVID-19 Vaccines/therapeutic use , Cross-Sectional Studies , COVID-19/epidemiology , COVID-19/prevention & control , Vaccination , Immunization , Pandemics/prevention & control
3.
Bone Marrow Transplant ; 42(11): 723-31, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18711352

ABSTRACT

Murine studies using anti-T-cell antibodies for conditioning in allogeneic SCT demonstrate engraftment with low rates of GVHD. On the basis of this preclinical model, we conditioned 30 patients with advanced hematologic malignancies with rabbit antithymocyte globulin (ATG) and TBI, to reduce rates of fatal acute GVHD. Patients were enrolled in two sequential groups: cohort 1 received ATG 10 mg/kg in divided doses (days -4 to -1)+200 cGy TBI (n=16), and cohort 2 received ATG (days -10 to -7)+450 cGy TBI (n=14). Median donor blood chimerism for the combined group was 94, 93 and 93% in the first, second and third months after transplant. Only three developed grade II acute GVHD despite 43% of patients receiving unrelated donor transplants. One-year survival was 71+/-11 and 54+/-14%, respectively, in recipients of related and unrelated donor SCT. Donor lymphocyte infusions were needed in 12 patients for the management of relapse and for mixed donor-recipient chimerism in 4 patients. We conclude that 10 mg/kg ATG and TBI allows engraftment with a low risk of acute GVHD; however, further dose optimization of ATG is required to achieve a balance between GVHD and disease relapse.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Graft vs Host Disease/therapy , Stem Cell Transplantation/methods , Transplantation Conditioning/methods , Adult , Aged , Animals , Antilymphocyte Serum/metabolism , Cohort Studies , Female , Humans , Lymphocytes/cytology , Male , Middle Aged , Rabbits , Treatment Outcome
4.
Oncogene ; 25(19): 2812-7, 2006 May 04.
Article in English | MEDLINE | ID: mdl-16331249

ABSTRACT

Proliferation of normal and malignant prostate epithelium is regulated by androgen stimulation via both the androgen receptor (AR)-positive stromal and epithelial cells. However, it is not known how AR expression is regulated in human prostate cells. We report that treatment of normal human prostate stromal cells (PrSCs) with type I IFN (alpha or beta), but not type II IFN (gamma), resulted in increased levels of AR protein. The maximal increase in AR protein levels was dependent on the dose and the duration of the IFN-alpha treatment. We found that the increase in AR protein levels was independent of de novo transcription and protein synthesis. Interestingly, the IFN-alpha treatment of PrSCs resulted in considerable nuclear accumulation of AR, stimulation of AR-mediated transcription of reporter genes, and retardation of cell proliferation. Furthermore, treatment of normal human prostate epithelial cells with IFNs (alpha, beta or gamma) also resulted in increased levels of AR protein. Together, our observations identify the androgen receptor as an IFN-regulated protein in normal human prostate stromal and epithelial cells and predict that IFN-induced levels of AR in prostate cells contribute to the regulation of androgen signaling.


Subject(s)
Antineoplastic Agents/pharmacology , Epithelial Cells/drug effects , Prostate/drug effects , Receptors, Androgen/metabolism , Stromal Cells/drug effects , Adult , Cell Proliferation/drug effects , Cells, Cultured , Dactinomycin/pharmacology , Epithelial Cells/metabolism , Humans , Interferon-alpha/pharmacology , Interferon-beta/pharmacology , Interferon-gamma/pharmacology , Male , Prostate/cytology , Prostate/metabolism , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Protein Synthesis Inhibitors/pharmacology , Receptors, Androgen/genetics , Stromal Cells/metabolism
5.
J Urol ; 164(6): 1982-6, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11061896

ABSTRACT

PURPOSE: We identify predictors of extraprostatic extension and positive surgical margins in patients with low risk prostate cancer (prostate specific antigen [PSA] 10 ng./ml. or less, biopsy Gleason score 7 or less and clinical stage T1c-2b). MATERIALS AND METHODS: From August 1997 to January 1999, 143 previously untreated patients underwent radical retropubic prostatectomy for clinically localized prostate cancer. A total of 62 patients were low risk, with PSA 10 ng./ml. or less, biopsy Gleason score 7 or less and clinical stage T1c-2b, and had sextant biopsy with separate pathological evaluation of each sextant cores. PSA, clinical stage, biopsy Gleason score, average percentage of cancer in the entire biopsy specimen, maximum percentage of cancer on the most involved core, number of cores involved and bilaterality were evaluated for association with extraprostatic extension, seminal vesicle involvement and positive surgical margins. RESULTS: Of the 62 patients 13 (21%) had extraprostatic extension, 6 (10%) seminal vesicle involvement and 20 (32%) positive surgical margins. Average percentage greater than 10% and maximum percentage greater than 25% were associated with extraprostatic extension (p = 0.01 and 0.004, respectively). Average percentage greater than 10%, maximum percentage greater than 25%, more than 2 cores involved and bilaterality were associated with positive surgical margins (p = 0.007, 0.01, 0.002 and 0.03, respectively). On multivariate analysis maximum percentage remained the only independent predictor of extraprostatic extension (p = 0.03), and the number of cores involved remained an independent predictor of positive surgical margins (p = 0.01). Biopsy Gleason score, PSA and clinical stage did not correlate with extraprostatic extension or positive surgical margins in this patient population. CONCLUSIONS: In low risk prostate cancer the extent of biopsy involvement significantly correlates with the risk of extraprostatic extension and positive surgical margins. Biopsy information should be considered when selecting and modifying treatment modalities.


Subject(s)
Biopsy , Prostatic Neoplasms/pathology , Aged , Humans , Male , Middle Aged , Neoplasm Invasiveness , Predictive Value of Tests , Prostate-Specific Antigen/analysis , Prostatectomy , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/surgery , Risk Factors , Seminal Vesicles/pathology
6.
Br J Cancer ; 82(10): 1709-16, 2000 May.
Article in English | MEDLINE | ID: mdl-10817508

ABSTRACT

Through a glucocorticoid-responsive promoter, glucocorticoids can regulate the transcription of the human papillomavirus (HPV) E6 and E7 viral genes which target the tumour suppressor proteins p53 and Rb respectively. In C4-1 cells, the glucocorticoid dexamethasone up-regulated HPV E6/E7 mRNA and decreased radiation-induced apoptosis. In contrast, dexamethasone had no effect on apoptosis of cells that either lack the HPV genome (C33-a) or in which HPV E6/E7 transcription is repressed by dexamethasone (SW756). Irradiated C4-1 cells showed increased p53 expression, while dexamethasone treatment prior to irradiation decreased p53 protein expression. In addition, p21 mRNA was regulated by irradiation and dexamethasone in accordance with the observed changes in p53. Overall, glucocorticoids decreased radiation-induced apoptosis in cervical carcinoma cells which exhibit increased HPV E6/E7 transcription and decreased p53 expression. Therefore, in HPV-infected cervical epithelial cells, p53-dependent apoptosis appears to depend upon the levels of HPV E6/E7 mRNA.


Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Apoptosis/drug effects , Dexamethasone/pharmacology , Glucocorticoids/pharmacology , Oncogene Proteins, Viral/drug effects , Tumor Suppressor Protein p53/drug effects , Uterine Cervical Neoplasms/virology , Apoptosis/genetics , Blotting, Western , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/metabolism , DNA Fragmentation , Female , Humans , Oncogene Proteins, Viral/metabolism , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/radiation effects , Tumor Suppressor Protein p53/metabolism , Uterine Cervical Neoplasms/metabolism , Uterine Cervical Neoplasms/physiopathology
7.
Gynecol Oncol ; 77(1): 177-82, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10739708

ABSTRACT

OBJECTIVE: Cervical carcinoma tumors containing radioresistant cells are associated with decreased local control and survival. Therefore, strategies to increase cell kill during radiotherapy have a clear rationale. It was previously determined that treatment with the corticosteroid dexamethasone increased radioresistance and decreased apoptosis in C4-1 cervical carcinoma cells. The goal of this study was to determine whether hormone antagonists, specifically Mifepristone (RU486), could reverse the effects of dexamethasone on clonogenic survival and apoptosis following gamma-irradiation. METHODS: Cervical carcinoma cell line C4-1 cells were exposed to 1 microM dexamethasone in the presence or absence of 1 microM Mifepristone (RU486), a hormone antagonist, and irradiation. Cells were analyzed for steroid-dependent HPV E6/E7 mRNA expression (by Northern blot analysis), clonogenic survival, and apoptosis (by Annexin V staining and the DNA fragmentation assay). In addition, p53 protein levels were determined by Western blot analysis. RESULTS: The hormone antagonist RU486 reversed dexamethasone-dependent upregulation of E6/E7 mRNA and restored radiation-induced p53 expression, apoptosis, and clonogenic survival to levels similar to those observed following irradiation alone. CONCLUSION: RU486 reverses glucocorticoid-dependent upregulation of HPV E6/E7, which corresponds to restoration of p53 expression, and restores radiosensitivity and apoptosis following gamma-irradiation. Therefore, it appears that along with radiation, RU486 may be a beneficial agent in the treatment of hormone-reactive cervical tumors.


Subject(s)
Apoptosis/drug effects , DNA-Binding Proteins , Dexamethasone/pharmacology , Hormone Antagonists/pharmacology , Mifepristone/pharmacology , Oncogene Proteins, Viral/metabolism , Radiation Tolerance/drug effects , Uterine Cervical Neoplasms/drug therapy , Cell Survival , DNA, Neoplasm/analysis , Female , Glucocorticoids/pharmacology , Humans , Oncogene Proteins, Viral/genetics , Papillomaviridae/genetics , Papillomavirus Infections , RNA, Messenger/biosynthesis , Tumor Cells, Cultured , Tumor Suppressor Protein p53/biosynthesis , Up-Regulation , Uterine Cervical Neoplasms/metabolism
8.
Radiother Oncol ; 47(2): 161-6, 1998 May.
Article in English | MEDLINE | ID: mdl-9683364

ABSTRACT

PURPOSE: To evaluate the effect of tumor bulk in relation to various tumor-related prognostic factors and treatment-related variables on local control and survival of patients with T1 N0 M0 squamous cell carcinoma of the glottis. MATERIALS AND METHODS: In 114 patients with T1 squamous cell carcinoma of the glottic larynx who were irradiated with curative intent, we determined the effect of tumor bulk in relation to mucosal extent (stage and anterior commissure involvement), histologic differentiation and various radiation factors, especially overall treatment time on local control and survival. Tumors were classified retrospectively as small surface lesions or bulky tumors. Seventy-seven patients had small lesions and 37 had bulky tumors. The anterior commissure was involved with cancer in 43 patients. The overall duration of irradiation ranged from 39 to 64 days. The median follow-up time was 6 years (range 5-24 years). RESULTS: The 5-year actuarial local control rate for all patients was 82% after radiotherapy and 92% after salvage laryngectomy. On univariate analysis, bulky tumors and tumors involving the anterior commissure showed an adverse effect on local control, whereas the overall duration of irradiation had a borderline significance. The actuarial local control rate was 91% for small tumors and 58% for bulky tumors (P = 0.0002), 88% when the anterior commissure was not involved and 67% when the anterior commissure was involved (P = 0.01) and 89% when radiation was given in less than 50 days and 73% when irradiation exceeded 50 days (P = 0.06). On multivariate analysis. tumor bulk was the only significant factor that affected local control (P = 0.02). The 5-year actuarial survival for all patients was 73% and the disease-free survival was 92%. CONCLUSION: This study shows that tumor bulk has a highly significant effect on the radiation control of T1 glottic cancer. Patients who had bulky tumors had lower local control and disease-free survival rates than those patients who had small tumors.


Subject(s)
Carcinoma, Squamous Cell/pathology , Laryngeal Neoplasms/pathology , Adult , Aged , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/radiotherapy , Female , Glottis , Humans , Laryngeal Neoplasms/mortality , Laryngeal Neoplasms/radiotherapy , Male , Middle Aged , Multivariate Analysis , Neoplasm Recurrence, Local , Prognosis , Retrospective Studies , Survival Rate
9.
Br J Cancer ; 70(4): 732-5, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7917930

ABSTRACT

In some clinical situations the endogenous production of glutamine may be insufficient to maintain optimal tissue structure and function such that glutamine becomes a conditionally essential amino acid. Studies in laboratory animals have demonstrated that glutamine supplementation can reduce the incidence and severity of cytotoxic-induced mucositis. This study examined the role of oral glutamine supplementation in the management of mucositis caused by 5-fluorouracil (5-FU) and folinic acid. Twenty-eight patients with gastrointestinal cancers were randomised to receive 16 g of glutamine per day for 8 days, or placebo, in a randomised double-blind trial before crossing over to the alternative supplement during the second treatment cycle. The supplement was well tolerated with no apparent adverse effects, but failed to have any significant effect on oral mucositis assessed by the patients or investigator. The possible reasons for this apparent lack of benefit are discussed.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Glutamine/therapeutic use , Stomatitis/chemically induced , Stomatitis/drug therapy , Administration, Oral , Cross-Over Studies , Double-Blind Method , Feasibility Studies , Female , Fluorouracil/administration & dosage , Fluorouracil/adverse effects , Gastrointestinal Neoplasms/blood , Gastrointestinal Neoplasms/drug therapy , Glutamine/adverse effects , Glutamine/blood , Humans , Leucovorin/administration & dosage , Leucovorin/adverse effects , Male , Mouth Mucosa/drug effects , Pilot Projects , Stomatitis/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...